Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Therapeutic drug monitoring of gabapentin: the applicability in patients with neuropathic pain

Full text
Author(s):
Priscila Akemi Yamamoto ; Jhohann Richard de Lima Benzi [2] ; Fabíola Dach [3] ; Natália Valadares de Moraes [4]
Total Authors: 4
Document type: Journal article
Source: Brazilian Journal of Pharmaceutical Sciences; v. 58, 2022-07-22.
Abstract

Abstract Gabapentin is an antiepileptic drug prescribed for several neuropathic pain conditions. This study aimed to evaluate gabapentin (GAB) trough plasma concentration range and the applicability of therapeutic drug monitoring in patients with neuropathic pain. Fifty-three patients with neuropathic pain, aged 20 to 75, received gabapentin as treatment for at least 7 days. Gabapentin plasma concentration was sampled before GAB administration and quantified by liquid chromatography with a UV detector. GAB trough plasma concentration ranged between 0.40 and 11.94 µg/mL in patients with chronic neuropathic pain. No differences were observed in terms of GAB plasma concentrations between responsive and non-responsive patients. Our data suggest that the reference ranges suggested in the literature for patients with epilepsy should not be used for patients with neuropathic pain. Therapeutic drug monitoring of GAB was shown to be an important tool to assess treatment adherence. (AU)

FAPESP's process: 15/25728-2 - Influence of the organic cation transporter 2 (OCT2) inhibitor cimetidine and experimental diabetes mellitus on kinetic disposition of gabapentin in rats
Grantee:Jhohann Richard de Lima Benzi
Support Opportunities: Scholarships in Brazil - Master